Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I.

Prevention of low density lipoprotein aggregation by high density lipoprotein or apolipoprotein A-I.

We have shown previously that low density lipoprotein (LDL) subjected to vortexing forms self-aggregates that are avidly phagocytosed by macrophages. That phagocytic uptake is mediated by the LDL receptor. We now show that LDL self-aggregation is strongly inhibited (80-95%) by the presence of high density lipoprotein (HDL) or apolipoprotein (apo) A-I. Another type of LDL aggregation, namely tha...

High density Lipoprotein; What to Measure: Quality or Quantity?

cholesterol/high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, non–high-density lipoprotein cholesterol, or low-density lipoprotein particle concentration and guideline categories of low-density lipoprotein cholesterol or non–high-density lipoprotein cholesterol

International clinical practice guidelines on dyslipidemia emphasize the importance of matching the use and intensity of statin therapy with the absolute risk of atherosclerotic cardiovascular disease (CVD). Indeed, independent of the baseline level of dyslipidemia, patients who have entered the intervention arms of randomized clinical trials of statin therapy with similar absolute risks of CVD...

Interactions of Apolipoprotein A-I with High-Density Lipoprotein Particles

Although the partitioning of apolipoprotein A-I (apoA-I) molecules in plasma between high-density lipoprotein (HDL)-bound and -unbound states is an integral part of HDL metabolism, the factors that control binding of apoA-I to HDL particles are poorly understood. To address this gap in knowledge, we investigated how the properties of the apoA-I tertiary structure domains and surface characteris...

Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy.

Although low-density lipoprotein (LDL) is widely recognized as the major atherogenic lipoprotein and the primary target of lipid-lowering therapy,1 other lipoprotein species nonetheless appear to be involved in atherogenesis. These include very low-density lipoproteins (VLDL), intermediate-density lipoproteins (IDL), and highdensity lipoproteins (HDL). Both VLDL and IDL are triglyceride-rich li...